296 related articles for article (PubMed ID: 34727985)
1. Simulation studies, 3D QSAR and molecular docking on a point mutation of protein kinase B with flavonoids targeting ovarian Cancer.
Ajjarapu SM; Tiwari A; Taj G; Singh DB; Singh S; Kumar S
BMC Pharmacol Toxicol; 2021 Nov; 22(1):68. PubMed ID: 34727985
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR, molecular docking, molecular dynamics, and ADME/T analysis of marketed and newly designed flavonoids as inhibitors of Bcl-2 family proteins for targeting U-87 glioblastoma.
Poustforoosh A; Faramarz S; Nematollahi MH; Hashemipour H; Tüzün B; Pardakhty A; Mehrabani M
J Cell Biochem; 2022 Feb; 123(2):390-405. PubMed ID: 34791695
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors.
Tripathy S; Azam MA; Jupudi S; Sahu SK
J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860
[TBL] [Abstract][Full Text] [Related]
4. A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer.
Thirumal Kumar D; Jain N; Evangeline J; Kamaraj B; Siva R; Zayed H; George Priya Doss C
Comput Biol Med; 2019 Dec; 115():103513. PubMed ID: 31698236
[TBL] [Abstract][Full Text] [Related]
5. Computational investigation of imidazopyridine analogs as protein kinase B (Akt1) allosteric inhibitors by using 3D-QSAR, molecular docking and molecular dynamics simulations.
Gu X; Wang Y; Wang M; Wang J; Li N
J Biomol Struct Dyn; 2021 Jan; 39(1):63-78. PubMed ID: 31838955
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and drug-likeness of antidiabetic flavonoids: Molecular docking and DFT study.
Bitew M; Desalegn T; Demissie TB; Belayneh A; Endale M; Eswaramoorthy R
PLoS One; 2021; 16(12):e0260853. PubMed ID: 34890431
[TBL] [Abstract][Full Text] [Related]
7. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
Chaudhari HK; Pahelkar A
Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
[TBL] [Abstract][Full Text] [Related]
8. Identification of Potent Small-Molecule PCSK9 Inhibitors Based on Quantitative Structure-Activity Relationship, Pharmacophore Modeling, and Molecular Docking Procedure.
Mahmoudi A; Butler AE; Banach M; Jamialahmadi T; Sahebkar A
Curr Probl Cardiol; 2023 Jun; 48(6):101660. PubMed ID: 36841313
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR and docking studies on ursolic acid derivatives for anticancer activity based on bladder cell line T24 targeting NF-kB pathway inhibition.
Yadav D; Nath Mishra B; Khan F
J Biomol Struct Dyn; 2019 Sep; 37(14):3822-3837. PubMed ID: 30261824
[TBL] [Abstract][Full Text] [Related]
10. Reconnoitering imidazopyridazines as anticancer agents based on virtual modelling approach: quantitative structure activity relationship, molecular docking and molecular dynamics.
Mangala K; Vinayak W; Aasiya C; Chandrakant B; Amol M; Kumar D; Kulkarni R
J Biomol Struct Dyn; 2024 Mar; 42(5):2392-2409. PubMed ID: 37160699
[TBL] [Abstract][Full Text] [Related]
11. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.
Chaudhari P; Bari S
Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560
[TBL] [Abstract][Full Text] [Related]
12. Investigating a Library of Flavonoids as Potential Inhibitors of a Cancer Therapeutic Target MEK2 Using in Silico Methods.
AlZahrani WM; AlGhamdi SA; Sohrab SS; Rehan M
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901876
[TBL] [Abstract][Full Text] [Related]
13. Exploring the Natural Compounds in Flavonoids for Their Potential Inhibition of Cancer Therapeutic Target MEK1 Using Computational Methods.
AlZahrani WM; AlGhamdi SA; Zughaibi TA; Rehan M
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215307
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
Oluić J; Nikolic K; Vucicevic J; Gagic Z; Filipic S; Agbaba D
Comb Chem High Throughput Screen; 2017 Aug; 20(4):292-303. PubMed ID: 28460621
[TBL] [Abstract][Full Text] [Related]
16. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
[TBL] [Abstract][Full Text] [Related]
17. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
18. Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1.
Mahajan P; Wadhwa B; Barik MR; Malik F; Nargotra A
Mol Divers; 2020 Feb; 24(1):45-60. PubMed ID: 30798436
[TBL] [Abstract][Full Text] [Related]
19. A Combined Approach of Pharmacophore Modeling, QSAR Study, Molecular Docking and In silico ADME/Tox Prediction of 4-Arylthio & 4-Aryloxy-3- Iodopyridine-2(1H)-one Analogs to Identify Potential Reverse Transcriptase Inhibitor: Anti-HIV Agents.
Panigrahi D; Mishra A; Sahu SK; Azam MA; Vyshaag CM
Med Chem; 2022; 18(1):51-87. PubMed ID: 33319692
[TBL] [Abstract][Full Text] [Related]
20. Computational Investigations of Coumarin Derivatives as Cyclindependent Kinase 9 Inhibitors Using 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation.
Liu S; Li Y; Wei X; Zhang R; Zhang Y; Guo C
Curr Comput Aided Drug Des; 2022; 18(5):363-380. PubMed ID: 35980073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
